Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project
Introduction The public–private ADVANCE collaboration developed and tested a system to generate evidence on vaccine benefits and risks using European electronic healthcare databases. In the safety of vaccines, background incidence rates are key to allow proper monitoring and assessment. The goals of...
Gespeichert in:
| Veröffentlicht in: | Drug safety 2021-03, Vol.44 (3), p.383-395 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 395 |
|---|---|
| container_issue | 3 |
| container_start_page | 383 |
| container_title | Drug safety |
| container_volume | 44 |
| creator | Willame, Corinne Dodd, Caitlin van der Aa, Lieke Picelli, Gino Emborg, Hanne-Dorthe Kahlert, Johnny Gini, Rosa Huerta, Consuelo Martín-Merino, Elisa McGee, Chris de Lusignan, Simon Roberto, Giuseppe Villa, Marco Weibel, Daniel Titievsky, Lina Sturkenboom, Miriam C. J. M. |
| description | Introduction
The public–private ADVANCE collaboration developed and tested a system to generate evidence on vaccine benefits and risks using European electronic healthcare databases. In the safety of vaccines, background incidence rates are key to allow proper monitoring and assessment. The goals of this study were to compute age-, sex-, and calendar-year stratified incidence rates of nine autoimmune diseases in seven European healthcare databases from four countries and to assess validity by comparing with published data.
Methods
Event rates were calculated for the following outcomes: acute disseminated encephalomyelitis, Bell’s palsy, Guillain–Barré syndrome, immune thrombocytopenia purpura, Kawasaki disease, optic neuritis, narcolepsy, systemic lupus erythematosus, and transverse myelitis. Cases were identified by diagnosis codes. Participating organizations/databases originated from Denmark, Italy, Spain, and the UK. The source population comprised all persons registered, with at least 1 year of data prior to the study start, or follow-up from birth. Stratified incidence rates were computed per database over the period 2003 to 2014.
Results
Between 2003 and 2014, 148,947 incident cases of nine autoimmune diseases were identified. Crude incidence rates were highest for Bell’s palsy [23.8/100,000 person-years (PYs), 95% confidence interval (CI) 23.6–24.1] and lowest for Kawasaki disease (0.7/100,000 PYs, 95% CI 0.6–0.7). Specific patterns were observed by sex, age, calendar time, and data sources. Rates were comparable with published estimates.
Conclusion
A range of autoimmune events could be identified in the ADVANCE system. Estimation of rates indicated consistency across selected European healthcare databases, as well as consistency with US published data. |
| doi_str_mv | 10.1007/s40264-020-01031-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7892524</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2493538641</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-a6911c0b37341b52c2ff70914091a69373a4011674117da0cb23dea96dd770b3</originalsourceid><addsrcrecordid>eNp9UV1rFDEUDaLYtfoHfJCAz6P3JpnJjA_CsF1tobRFiq8hk8l0s-wma5Ip-O_NdmvVFx9C4J6Pey6HkLcIHxBAfkwCWCMqYFABAscKn5EFouwq7AR7ThaAKKq6w-aEvEppAwAta9qX5IRz0TAp2wXxF9640Xpj6TedbaJhov2cg9vtZm_pmUtWpzJ2nq7mGPZWe3pu9TavjY4F11kPB8In2tNl8Dm6Yc4u-INPXlvan33vr5YrehPDxpr8mryY9DbZN4__Kbn9srpdnleX118vlv1lZWoBudJNh2hg4JILHGpm2DRJ6FCUV7Ay1qIc10hRzh01mIHx0equGUcpi-yUfD7a7udhZ0djSzC9Vfvodjr-VEE79S_i3VrdhXsl247VTBSD948GMfyYbcpqE-boS2TFRMdr3jYCC4sdWSaGlKKdnjYgqENF6liRKhWph4rUQfTu72xPkt-dFAI_ElKB_J2Nf3b_x_YXOPubxQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2493538641</pqid></control><display><type>article</type><title>Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Willame, Corinne ; Dodd, Caitlin ; van der Aa, Lieke ; Picelli, Gino ; Emborg, Hanne-Dorthe ; Kahlert, Johnny ; Gini, Rosa ; Huerta, Consuelo ; Martín-Merino, Elisa ; McGee, Chris ; de Lusignan, Simon ; Roberto, Giuseppe ; Villa, Marco ; Weibel, Daniel ; Titievsky, Lina ; Sturkenboom, Miriam C. J. M.</creator><creatorcontrib>Willame, Corinne ; Dodd, Caitlin ; van der Aa, Lieke ; Picelli, Gino ; Emborg, Hanne-Dorthe ; Kahlert, Johnny ; Gini, Rosa ; Huerta, Consuelo ; Martín-Merino, Elisa ; McGee, Chris ; de Lusignan, Simon ; Roberto, Giuseppe ; Villa, Marco ; Weibel, Daniel ; Titievsky, Lina ; Sturkenboom, Miriam C. J. M.</creatorcontrib><description>Introduction
The public–private ADVANCE collaboration developed and tested a system to generate evidence on vaccine benefits and risks using European electronic healthcare databases. In the safety of vaccines, background incidence rates are key to allow proper monitoring and assessment. The goals of this study were to compute age-, sex-, and calendar-year stratified incidence rates of nine autoimmune diseases in seven European healthcare databases from four countries and to assess validity by comparing with published data.
Methods
Event rates were calculated for the following outcomes: acute disseminated encephalomyelitis, Bell’s palsy, Guillain–Barré syndrome, immune thrombocytopenia purpura, Kawasaki disease, optic neuritis, narcolepsy, systemic lupus erythematosus, and transverse myelitis. Cases were identified by diagnosis codes. Participating organizations/databases originated from Denmark, Italy, Spain, and the UK. The source population comprised all persons registered, with at least 1 year of data prior to the study start, or follow-up from birth. Stratified incidence rates were computed per database over the period 2003 to 2014.
Results
Between 2003 and 2014, 148,947 incident cases of nine autoimmune diseases were identified. Crude incidence rates were highest for Bell’s palsy [23.8/100,000 person-years (PYs), 95% confidence interval (CI) 23.6–24.1] and lowest for Kawasaki disease (0.7/100,000 PYs, 95% CI 0.6–0.7). Specific patterns were observed by sex, age, calendar time, and data sources. Rates were comparable with published estimates.
Conclusion
A range of autoimmune events could be identified in the ADVANCE system. Estimation of rates indicated consistency across selected European healthcare databases, as well as consistency with US published data.</description><identifier>ISSN: 0114-5916</identifier><identifier>EISSN: 1179-1942</identifier><identifier>DOI: 10.1007/s40264-020-01031-1</identifier><identifier>PMID: 33462778</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Age ; Autoimmune diseases ; Autoimmune Diseases - epidemiology ; Bell Palsy - epidemiology ; Bell's palsy ; Calendars ; Chronic conditions ; Codes ; Collaboration ; Confidence intervals ; Consistency ; Data processing ; Delivery of Health Care ; Drug Safety and Pharmacovigilance ; Encephalomyelitis ; Guillain-Barre syndrome ; Health care ; Humans ; Idiopathic thrombocytopenic purpura ; Incidence ; Kawasaki disease ; Lupus ; Medicine ; Medicine & Public Health ; Mucocutaneous Lymph Node Syndrome ; Myelitis ; Narcolepsy ; Neuritis ; Optic neuritis ; Original ; Original Research Article ; Paralysis ; Pharmacology/Toxicology ; Population ; Primary care ; Purpura ; Sex ; Sleep disorders ; Software ; Systemic lupus erythematosus ; Thrombocytopenia ; Vaccination ; Vaccines</subject><ispartof>Drug safety, 2021-03, Vol.44 (3), p.383-395</ispartof><rights>The Author(s) 2021</rights><rights>Copyright Springer Nature B.V. Mar 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-a6911c0b37341b52c2ff70914091a69373a4011674117da0cb23dea96dd770b3</citedby><cites>FETCH-LOGICAL-c540t-a6911c0b37341b52c2ff70914091a69373a4011674117da0cb23dea96dd770b3</cites><orcidid>0000-0002-6310-6019</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40264-020-01031-1$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40264-020-01031-1$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33462778$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Willame, Corinne</creatorcontrib><creatorcontrib>Dodd, Caitlin</creatorcontrib><creatorcontrib>van der Aa, Lieke</creatorcontrib><creatorcontrib>Picelli, Gino</creatorcontrib><creatorcontrib>Emborg, Hanne-Dorthe</creatorcontrib><creatorcontrib>Kahlert, Johnny</creatorcontrib><creatorcontrib>Gini, Rosa</creatorcontrib><creatorcontrib>Huerta, Consuelo</creatorcontrib><creatorcontrib>Martín-Merino, Elisa</creatorcontrib><creatorcontrib>McGee, Chris</creatorcontrib><creatorcontrib>de Lusignan, Simon</creatorcontrib><creatorcontrib>Roberto, Giuseppe</creatorcontrib><creatorcontrib>Villa, Marco</creatorcontrib><creatorcontrib>Weibel, Daniel</creatorcontrib><creatorcontrib>Titievsky, Lina</creatorcontrib><creatorcontrib>Sturkenboom, Miriam C. J. M.</creatorcontrib><title>Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project</title><title>Drug safety</title><addtitle>Drug Saf</addtitle><addtitle>Drug Saf</addtitle><description>Introduction
The public–private ADVANCE collaboration developed and tested a system to generate evidence on vaccine benefits and risks using European electronic healthcare databases. In the safety of vaccines, background incidence rates are key to allow proper monitoring and assessment. The goals of this study were to compute age-, sex-, and calendar-year stratified incidence rates of nine autoimmune diseases in seven European healthcare databases from four countries and to assess validity by comparing with published data.
Methods
Event rates were calculated for the following outcomes: acute disseminated encephalomyelitis, Bell’s palsy, Guillain–Barré syndrome, immune thrombocytopenia purpura, Kawasaki disease, optic neuritis, narcolepsy, systemic lupus erythematosus, and transverse myelitis. Cases were identified by diagnosis codes. Participating organizations/databases originated from Denmark, Italy, Spain, and the UK. The source population comprised all persons registered, with at least 1 year of data prior to the study start, or follow-up from birth. Stratified incidence rates were computed per database over the period 2003 to 2014.
Results
Between 2003 and 2014, 148,947 incident cases of nine autoimmune diseases were identified. Crude incidence rates were highest for Bell’s palsy [23.8/100,000 person-years (PYs), 95% confidence interval (CI) 23.6–24.1] and lowest for Kawasaki disease (0.7/100,000 PYs, 95% CI 0.6–0.7). Specific patterns were observed by sex, age, calendar time, and data sources. Rates were comparable with published estimates.
Conclusion
A range of autoimmune events could be identified in the ADVANCE system. Estimation of rates indicated consistency across selected European healthcare databases, as well as consistency with US published data.</description><subject>Age</subject><subject>Autoimmune diseases</subject><subject>Autoimmune Diseases - epidemiology</subject><subject>Bell Palsy - epidemiology</subject><subject>Bell's palsy</subject><subject>Calendars</subject><subject>Chronic conditions</subject><subject>Codes</subject><subject>Collaboration</subject><subject>Confidence intervals</subject><subject>Consistency</subject><subject>Data processing</subject><subject>Delivery of Health Care</subject><subject>Drug Safety and Pharmacovigilance</subject><subject>Encephalomyelitis</subject><subject>Guillain-Barre syndrome</subject><subject>Health care</subject><subject>Humans</subject><subject>Idiopathic thrombocytopenic purpura</subject><subject>Incidence</subject><subject>Kawasaki disease</subject><subject>Lupus</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mucocutaneous Lymph Node Syndrome</subject><subject>Myelitis</subject><subject>Narcolepsy</subject><subject>Neuritis</subject><subject>Optic neuritis</subject><subject>Original</subject><subject>Original Research Article</subject><subject>Paralysis</subject><subject>Pharmacology/Toxicology</subject><subject>Population</subject><subject>Primary care</subject><subject>Purpura</subject><subject>Sex</subject><subject>Sleep disorders</subject><subject>Software</subject><subject>Systemic lupus erythematosus</subject><subject>Thrombocytopenia</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>0114-5916</issn><issn>1179-1942</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9UV1rFDEUDaLYtfoHfJCAz6P3JpnJjA_CsF1tobRFiq8hk8l0s-wma5Ip-O_NdmvVFx9C4J6Pey6HkLcIHxBAfkwCWCMqYFABAscKn5EFouwq7AR7ThaAKKq6w-aEvEppAwAta9qX5IRz0TAp2wXxF9640Xpj6TedbaJhov2cg9vtZm_pmUtWpzJ2nq7mGPZWe3pu9TavjY4F11kPB8In2tNl8Dm6Yc4u-INPXlvan33vr5YrehPDxpr8mryY9DbZN4__Kbn9srpdnleX118vlv1lZWoBudJNh2hg4JILHGpm2DRJ6FCUV7Ay1qIc10hRzh01mIHx0equGUcpi-yUfD7a7udhZ0djSzC9Vfvodjr-VEE79S_i3VrdhXsl247VTBSD948GMfyYbcpqE-boS2TFRMdr3jYCC4sdWSaGlKKdnjYgqENF6liRKhWph4rUQfTu72xPkt-dFAI_ElKB_J2Nf3b_x_YXOPubxQ</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Willame, Corinne</creator><creator>Dodd, Caitlin</creator><creator>van der Aa, Lieke</creator><creator>Picelli, Gino</creator><creator>Emborg, Hanne-Dorthe</creator><creator>Kahlert, Johnny</creator><creator>Gini, Rosa</creator><creator>Huerta, Consuelo</creator><creator>Martín-Merino, Elisa</creator><creator>McGee, Chris</creator><creator>de Lusignan, Simon</creator><creator>Roberto, Giuseppe</creator><creator>Villa, Marco</creator><creator>Weibel, Daniel</creator><creator>Titievsky, Lina</creator><creator>Sturkenboom, Miriam C. J. M.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7T2</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6310-6019</orcidid></search><sort><creationdate>20210301</creationdate><title>Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project</title><author>Willame, Corinne ; Dodd, Caitlin ; van der Aa, Lieke ; Picelli, Gino ; Emborg, Hanne-Dorthe ; Kahlert, Johnny ; Gini, Rosa ; Huerta, Consuelo ; Martín-Merino, Elisa ; McGee, Chris ; de Lusignan, Simon ; Roberto, Giuseppe ; Villa, Marco ; Weibel, Daniel ; Titievsky, Lina ; Sturkenboom, Miriam C. J. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-a6911c0b37341b52c2ff70914091a69373a4011674117da0cb23dea96dd770b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age</topic><topic>Autoimmune diseases</topic><topic>Autoimmune Diseases - epidemiology</topic><topic>Bell Palsy - epidemiology</topic><topic>Bell's palsy</topic><topic>Calendars</topic><topic>Chronic conditions</topic><topic>Codes</topic><topic>Collaboration</topic><topic>Confidence intervals</topic><topic>Consistency</topic><topic>Data processing</topic><topic>Delivery of Health Care</topic><topic>Drug Safety and Pharmacovigilance</topic><topic>Encephalomyelitis</topic><topic>Guillain-Barre syndrome</topic><topic>Health care</topic><topic>Humans</topic><topic>Idiopathic thrombocytopenic purpura</topic><topic>Incidence</topic><topic>Kawasaki disease</topic><topic>Lupus</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mucocutaneous Lymph Node Syndrome</topic><topic>Myelitis</topic><topic>Narcolepsy</topic><topic>Neuritis</topic><topic>Optic neuritis</topic><topic>Original</topic><topic>Original Research Article</topic><topic>Paralysis</topic><topic>Pharmacology/Toxicology</topic><topic>Population</topic><topic>Primary care</topic><topic>Purpura</topic><topic>Sex</topic><topic>Sleep disorders</topic><topic>Software</topic><topic>Systemic lupus erythematosus</topic><topic>Thrombocytopenia</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Willame, Corinne</creatorcontrib><creatorcontrib>Dodd, Caitlin</creatorcontrib><creatorcontrib>van der Aa, Lieke</creatorcontrib><creatorcontrib>Picelli, Gino</creatorcontrib><creatorcontrib>Emborg, Hanne-Dorthe</creatorcontrib><creatorcontrib>Kahlert, Johnny</creatorcontrib><creatorcontrib>Gini, Rosa</creatorcontrib><creatorcontrib>Huerta, Consuelo</creatorcontrib><creatorcontrib>Martín-Merino, Elisa</creatorcontrib><creatorcontrib>McGee, Chris</creatorcontrib><creatorcontrib>de Lusignan, Simon</creatorcontrib><creatorcontrib>Roberto, Giuseppe</creatorcontrib><creatorcontrib>Villa, Marco</creatorcontrib><creatorcontrib>Weibel, Daniel</creatorcontrib><creatorcontrib>Titievsky, Lina</creatorcontrib><creatorcontrib>Sturkenboom, Miriam C. J. M.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Willame, Corinne</au><au>Dodd, Caitlin</au><au>van der Aa, Lieke</au><au>Picelli, Gino</au><au>Emborg, Hanne-Dorthe</au><au>Kahlert, Johnny</au><au>Gini, Rosa</au><au>Huerta, Consuelo</au><au>Martín-Merino, Elisa</au><au>McGee, Chris</au><au>de Lusignan, Simon</au><au>Roberto, Giuseppe</au><au>Villa, Marco</au><au>Weibel, Daniel</au><au>Titievsky, Lina</au><au>Sturkenboom, Miriam C. J. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project</atitle><jtitle>Drug safety</jtitle><stitle>Drug Saf</stitle><addtitle>Drug Saf</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>44</volume><issue>3</issue><spage>383</spage><epage>395</epage><pages>383-395</pages><issn>0114-5916</issn><eissn>1179-1942</eissn><abstract>Introduction
The public–private ADVANCE collaboration developed and tested a system to generate evidence on vaccine benefits and risks using European electronic healthcare databases. In the safety of vaccines, background incidence rates are key to allow proper monitoring and assessment. The goals of this study were to compute age-, sex-, and calendar-year stratified incidence rates of nine autoimmune diseases in seven European healthcare databases from four countries and to assess validity by comparing with published data.
Methods
Event rates were calculated for the following outcomes: acute disseminated encephalomyelitis, Bell’s palsy, Guillain–Barré syndrome, immune thrombocytopenia purpura, Kawasaki disease, optic neuritis, narcolepsy, systemic lupus erythematosus, and transverse myelitis. Cases were identified by diagnosis codes. Participating organizations/databases originated from Denmark, Italy, Spain, and the UK. The source population comprised all persons registered, with at least 1 year of data prior to the study start, or follow-up from birth. Stratified incidence rates were computed per database over the period 2003 to 2014.
Results
Between 2003 and 2014, 148,947 incident cases of nine autoimmune diseases were identified. Crude incidence rates were highest for Bell’s palsy [23.8/100,000 person-years (PYs), 95% confidence interval (CI) 23.6–24.1] and lowest for Kawasaki disease (0.7/100,000 PYs, 95% CI 0.6–0.7). Specific patterns were observed by sex, age, calendar time, and data sources. Rates were comparable with published estimates.
Conclusion
A range of autoimmune events could be identified in the ADVANCE system. Estimation of rates indicated consistency across selected European healthcare databases, as well as consistency with US published data.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>33462778</pmid><doi>10.1007/s40264-020-01031-1</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-6310-6019</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0114-5916 |
| ispartof | Drug safety, 2021-03, Vol.44 (3), p.383-395 |
| issn | 0114-5916 1179-1942 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7892524 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Age Autoimmune diseases Autoimmune Diseases - epidemiology Bell Palsy - epidemiology Bell's palsy Calendars Chronic conditions Codes Collaboration Confidence intervals Consistency Data processing Delivery of Health Care Drug Safety and Pharmacovigilance Encephalomyelitis Guillain-Barre syndrome Health care Humans Idiopathic thrombocytopenic purpura Incidence Kawasaki disease Lupus Medicine Medicine & Public Health Mucocutaneous Lymph Node Syndrome Myelitis Narcolepsy Neuritis Optic neuritis Original Original Research Article Paralysis Pharmacology/Toxicology Population Primary care Purpura Sex Sleep disorders Software Systemic lupus erythematosus Thrombocytopenia Vaccination Vaccines |
| title | Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T08%3A07%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20Rates%20of%20Autoimmune%20Diseases%20in%20European%20Healthcare%20Databases:%20A%20Contribution%20of%20the%20ADVANCE%20Project&rft.jtitle=Drug%20safety&rft.au=Willame,%20Corinne&rft.date=2021-03-01&rft.volume=44&rft.issue=3&rft.spage=383&rft.epage=395&rft.pages=383-395&rft.issn=0114-5916&rft.eissn=1179-1942&rft_id=info:doi/10.1007/s40264-020-01031-1&rft_dat=%3Cproquest_pubme%3E2493538641%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2493538641&rft_id=info:pmid/33462778&rfr_iscdi=true |